New pneumonia vaccine trial aims to shield 3,000 kids from deadly infection
NCT ID NCT06617715
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine is safe and triggers a strong immune response compared to an existing vaccine. If it works, it could help prevent serious diseases like pneumonia and meningitis in young children.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
13-valent pneumococcal conjugate vaccine (PCV13)
What this could lead to
If successful, this could provide a new option to protect infants and children from serious pneumococcal infections like pneumonia and meningitis.
What could go wrong
This is a large Phase 3 trial, but the vaccine may not prove as effective or safe as existing ones. Results are still pending.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Provincial Center for Disease Control and Prevention
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-••••